Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.（BDTX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · BDTX · 截至 2025年9月30日
股东结构概览
90
机构持有人数
▼ 3 vs Q2
$146.97M
机构持仓总市值
▲ $51.21M vs Q2
57.30M
总流通股
freeFloat 80.33%
38.78M
13F 申报持股数
▲ 164,219 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
BDTX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 10.74M | 18.91% | 18.91% | $40.72B | Nov 14, 2025 | ▲ 232.0K |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 5.55M | 9.77% | 9.77% | $21.03B | Nov 14, 2025 | ▼ 50.0K |
NEA MANAGEMENT COMPANY, LLC biological products, (no diagnostic substances) | 4.45M | 7.83% | 7.83% | $16.86B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.19M | 3.85% | 3.85% | $8.30B | Nov 7, 2025 | ▲ 85.8K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.07M | 3.64% | 3.64% | $7.85B | Nov 14, 2025 | — held |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 1.30M | 2.29% | 2.29% | $4.92B | Nov 13, 2025 | ▲ 561.3K |
SIREN, L.L.C. biological products, (no diagnostic substances) | 1.05M | 1.84% | 1.84% | $3.97B | Nov 13, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.03M | 1.81% | 1.81% | $3.90B | Nov 12, 2025 | ▼ 62.8K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 896.9K | 1.58% | 1.58% | $3.40B | Nov 13, 2025 | ▲ 758.7K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 850.3K | 1.50% | 1.50% | $3.22B | Nov 14, 2025 | ▼ 94.5K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
26
增持
+4.13M 股8
新建仓
首次建仓9
减持
−574.1K 股0
清仓
完全退出净股数变化（前50家）
+3.55M
+4.13M / −574.1K
净新增持仓人
+25
新建 8 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
BDTX 内幕交易记录
数据来源：SEC Form 4
7
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Behbahani Ali director | Mar 20, 2026 | Award | 6,919 | $2.15 | $14.9K | 93.6K | Form 4 ↗ |
Raman Prakash director | Mar 20, 2026 | Award | 6,105 | $2.15 | $13.1K | 37.1K | Form 4 ↗ |
Jones Erika SEE REMARKS | Jan 21, 2026 | Award | 200,000 | $2.57 | $514.0K | 200.0K | Form 4 ↗ |
Hatzis-Schoch Brent SEE REMARKS | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Buck Elizabeth CHIEF SCIENTIFIC OFFICER | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Yurasov Sergey CHIEF MEDICAL OFFICER | Jan 21, 2026 | Award | 250,000 | $2.57 | $642.5K | 250.0K | Form 4 ↗ |
Velleca Mark A. PRESIDENT & CEO | Jan 21, 2026 | Award | 600,000 | $2.57 | $1.54M | 600.0K | Form 4 ↗ |
Behbahani Ali director | Dec 12, 2025 | Award | 5,208 | $2.76 | $14.4K | 86.6K | Form 4 ↗ |
Raman Prakash director | Dec 12, 2025 | Award | 4,665 | $2.76 | $12.9K | 31.0K | Form 4 ↗ |
Behbahani Ali director | Sep 19, 2025 | Award | 4,291 | $3.35 | $14.4K | 81.4K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Black Diamond Therapeutics, Inc.（BDTX）主要由机构投资者持有，机构持股比例约为 67.7%。公司内部人员持股约 19.67%，散户及公众持股约占剩余的 12.65%。
Black Diamond Therapeutics, Inc. 最大机构股东为 T. ROWE PRICE INVESTMENT MANAGEMENT, INC.，截至 September 30, 2025 持有约 10.74 million 股，占总流通股的 18.91%。
目前共有 90 家机构持有 BDTX 股票，合计持仓市值约 $146,973,938，数据来源为最新 SEC 13F 申报。
常见问题
BDTX ownershipBlack Diamond Therapeutics, Inc.（BDTX）主要由机构投资者持有，机构持股约 67.7%。最大股东为 T. ROWE PRICE INVESTMENT MANAGEMENT, INC.，持股比例 18.91%。内部人员持股约 19.67%。数据来源 SEC Form 13F，截至 September 30, 2025。